1 active not recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Hatim Husain: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC Nivolumab, Oxaliplatin, Ipilimumab - Advanced NSCLC | Phase 1 / Phase 2 | Active not recruiting | Hatim Husain | 30 | 2019-08-14 | 2025-05-28 |
Ipilimumab (1) · Nivolumab (1) · Oxaliplatin (1)
United States (1)